With a minimum of 73.5 months of follow-up, nivolumab plus ipilimumab showed a benefit in overall survival in patients with treatment-naive stage IV or recurrent non–small cell lung cancer with no ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results